ESALY - Eisai Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
57.87
+0.48 (+0.84%)
At close: 3:46PM EDT
Stock chart is not supported by your current browser
Previous Close57.39
Open58.09
Bid0.00 x 0
Ask0.00 x 0
Day's Range57.55 - 58.14
52 Week Range52.26 - 101.80
Volume3,557
Avg. Volume11,363
Market Cap16.037B
Beta (3Y Monthly)0.81
PE Ratio (TTM)27.81
EPS (TTM)2.08
Earnings DateN/A
Forward Dividend & Yield1.48 (2.53%)
Ex-Dividend Date2019-03-27
1y Target Est80.95
Trade prices are not sourced from all markets
  • Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
    Investor's Business Daily2 days ago

    Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

    Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

  • Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
    Zacks26 days ago

    Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

    Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

  • Catalent Acquires Gene Therapy Leader Paragon Bioservices
    Zacks26 days ago

    Catalent Acquires Gene Therapy Leader Paragon Bioservices

    Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

  • Key Drugs in Merck’s Oncology Portfolio
    Market Realistlast month

    Key Drugs in Merck’s Oncology Portfolio

    Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in

  • CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher
    Zackslast month

    CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher

    CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
    Zackslast month

    Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

    Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

  • Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
    Zackslast month

    Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

    Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...

  • Health-care earnings: ‘Medicare for all’ looms large
    MarketWatch2 months ago

    Health-care earnings: ‘Medicare for all’ looms large

    Health-care earnings begin in earnest this week. Centene Corp. reported on Tuesday, and Anthem Inc., Biogen Inc., Boston Scientific Corp. and Novartis AG are set to report Wednesday.

  • Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
    Zacks2 months ago

    Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

    Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

  • Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
    Zacks2 months ago

    Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

    Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

  • United Therapeutics Discontinues PAH Drug After Study Fails
    Zacks2 months ago

    United Therapeutics Discontinues PAH Drug After Study Fails

    United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 28) Baxter International Inc (NYSE: BAX ) Constellation ...

  • Biogen stock plummets 28% after company halts Alzheimer’s trials
    MarketWatch3 months ago

    Biogen stock plummets 28% after company halts Alzheimer’s trials

    Shares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an investigational drug designed to treat symptoms of early Alzheimer’s disease.

  • Reuters3 months ago

    Nikkei posts biggest daily drop in 3 months on renewed fears of global slowdown

    On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007. The inversion of the Treasury yield curve suggested the world's largest economy could slide into recession and reignited fears of a deepening slowdown in the global economy. "Insurers react negatively as it becomes harder for them to manage assets," said Eiji Kinouchi, chief technical analyst at Daiwa Securities.

  • Reuters3 months ago

    Nikkei hits five-week low on renewed fears of global slowdown

    Japan's Nikkei sold off sharply on Monday as investors moved into bonds and other assets perceived as safe amid renewed fears of a global economic slowdown. The benchmark index was on track for its steepest daily fall in percentage terms since losing 5 percent in late December. On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007.

  • Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study
    Investor's Business Daily3 months ago

    Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study

    Biogen and Japanese pharma Eisai announced a new study in Alzheimer's disease treatment Friday following a high-profile failure on Thursday that sent Biogen stock into a tailspin.

  • Benzinga3 months ago

    Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

    Mizuho Securities analyst Salim Syed downgraded Biogen from Buy to Neutral and slashed the price target from $416 to $235. UBS analyst Carter Gould downgraded Biogen from Buy to Neutral and reduced the price target from $395 to $242. Morgan Stanley analyst Matthew Harrison downgraded shares from Overweight to Underweight and slashed the price target from $401 to $210.

  • Benzinga3 months ago

    Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback

    Eisai, which is partnering with Biogen Inc (NASDAQ: BIIB) on Alzheimer's research, announced the initiation of a global Phase 3 clinical study Thursday, dubbed Clarity AD/Study 301, of BAN2401, which is being evaluated in patients with early Alzheimer's disease. BAN2401 is a monoclonal antibody that acts against beta-amyloid protein that forms clumps called plaques in the brain, impairing connections between brain cells and triggering inflammation, leading to cell death, both of which are responsible for the onset of Alzheimer's.

  • MarketWatch3 months ago

    Biogen stock price target cut to $247 from $341 at SVB Leerink

    SVB Leerink analysts cut their price target on shares of Biogen Inc. to $247 from $341 on Friday. "The uncertainties about the outlook for their MS and SMA franchises are significant," wrote analysts led by Geoffrey Porges, who maintained their market perform rating on the stock. Porges said he and his team "assume that the company takes the responsible decision to terminate all further investments in beta amyloid-directed medicines (which has not occurred), and saves their investors the cash and saves patients and investigators from the burden of such studies. If Biogen does not make this decision, then our adjusted expense forecast could be too low, with further negative effects on our valuation even compared to our new PT." However, despite doubts about the efficacy of drugs based on the amyloid hypothesis, Biogen is forging ahead with its next amyloid-based trial; drug development partner Eisai Co. Ltd. announced on Friday the initiation of another Phase 3 trial, this time evaluating BAN2401, a monoclonal antibody that binds to neutralize and eliminate toxic beta amyloid aggregates. Biogen's stock, which fell 1.1% in premarket trade Friday, plunged 29% on Thursday after the company announced it was discontinuing trials for Alzheimer's drug aducanumab. Shares of the drugmaker have fallen 25% in the year to date, while the S&P 500 has gained 13.9%.

  • Reuters3 months ago

    Nikkei ends flat despite strong chip makers

    Japan's Nikkei ended little changed on Friday as chip-related stocks offset weakness in financial stocks and drugmakers, which tumbled after Eisai said it will end its Alzheimer drug trials. Advantest Corp soared 6.2 percent and Tokyo Electron surged 5.2 percent. "The U.S. tech sector's recovery is indicating that growth stocks are making a come back," said Norihiro Fujito, a chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities.

  • Eisai starts phase 3 trials for second Alzheimer's drug after first's failure
    Reuters3 months ago

    Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

    Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab. On Friday, Eisai was untraded, flooded with sell orders at 7,565 yen, almost 17 percent lower than its previous close. The demise of aducanumab came after independent experts determined the trials had little hope of succeeding, marking the latest setback in the quest to treat a mind-wasting disease that affects 5.7 million people in the United States alone.

  • Reuters3 months ago

    Nikkei falls as financials drag; Eisai indicated to dive

    Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials. Financial stocks faced a sell-off after the spread between the three-month Treasury bill yield and the 10-year note yield shrank to its narrowest level since August 2007 on Thursday in the wake of the U.S. Federal Reserve's decision to cease tightening monetary policy.

  • Reuters3 months ago

    Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

    Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab. The decision, which wiped $18 billion off the value on Biogen on Thursday, marks a major setback in the quest to find a treatment for the mind-wasting disease and came after experts determined the trials had little hope of succeeding. Eisai shares were hit with sell orders at 7,565 yen, down nearly 17 percent from Wednesday's close of 9,065 yen, the most it could fall on Friday under exchange rules.